Table 1.
Patient demographics and clinical characteristics
| Parameter | No. |
|---|---|
| Sex | |
| Male | 22 |
| Female | 15 |
| Median age, years | 58 |
| Range | 27-77 |
| ECOG performance status | |
| 0 | 20 |
| 1 | 17 |
| Tumor biopsy sites | |
| Liver | 15 |
| Abdominal wall | 9 |
| Rectum/vaginal wall | 4 |
| Scalp | 2 |
| Lymph node | 5 |
| Prior lines of treatment | |
| 2-3 | 18 (51%) |
| ≥4 | 17 (49%) |
| Prior treatment | |
| Bevacizumab | 15 (43%) |
| Cetuximab | 15 (43%) |
| Baseline organ function | |
| AST (U/L) | 34.6 ± 22.4 |
| ALT (U/L) | 23.5 ± 10.9 |
| Total bilirubin (μmol/L) | 10.1 ± 5.8 |
| Creatinine (μmol/L) | 66.9 ± 27.0 |
37 patients screened; 35 commenced therapy, 2 failed screening.
8 patients did not complete cycle 2 for tumour biopsy and evaluation of response.
11 patients did not have second biopsy.